Condor uses AI to reconcile CRO and site-payment vendor data against trial activity and contracted rates, uncovering site performance patterns, assessing costs relative to site performance, and improving forecasting accuracy
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ — Condor Software, the AI platform for biopharma R&D teams, today introduced AI-powered investigator grants intelligence, a new capability that lets sponsors ingest payment data from their CROs and site-payment vendors and automatically reconcile it against their own trial activity and site contracts. R&D teams can now instantly see site-level cost and performance patterns, assess costs relative to site performance, and improve forecasting accuracy — bringing greater financial visibility and accountability to investigator grants spend.
Investigator grants account for up to half of total per-trial cost, and clinical activity can generate tens of thousands of payment lines in a single mid-sized trial. Most teams outsource grant payments to CROs or payments vendors who typically share summary reports — sometimes only a single dollar figure — with no visibility into which visits, procedures, or site fees it represents. Without line-level verification, sponsors pay for visits that never happened, procedures billed at off-contract rates, and duplicate charges, and they struggle to effectively forecast and understand how sites perform. Sponsors that receive details from CROs and payment vendors must reconcile thousands of payment lines by hand in spreadsheets, which is painstaking and error-prone.
“Every investigator grant has three versions of the truth: what the contract says should happen, what your own trial data says happened, and what the vendor says happened,” said Condor VP of Product Nim Fox. “Sponsors already had the first two in Condor. Vendor-level data was the missing piece. But even when teams can get it, it arrives in the vendor’s format, split and combined differently from how they track the work. We use AI to close that gap, so teams know whether they’re being overbilled, what’s missing, and what’s coming, instead of taking the vendor’s number on faith, and can then build more accurate forecasts. Today’s announcement is another great example of how we are leveraging AI to automate manual work that slows biopharma R&D teams down.”
How AI-Powered Investigator Grants Intelligence Works
Sponsors ingest vendor payment reports, procedure data, and visit data, from accrual reports to detailed site invoices, directly into Condor. Built on Condor’s clinical and financial knowledge graph, the Biopharma R&D Graph, the platform’s AI normalizes each vendor’s format and maps every line to the sponsor’s EDC activity, protocols, and site contracts in Condor. Once reconciled, Condor surfaces:
- Overbilling and pricing discrepancies. Invoice lines are checked against contracted rates, amendments, and terms, with wrong prices, off-contract charges, and duplicates flagged automatically.
- Missing and unmatched payments. Payments with no recorded activity behind them, sites paid with no subject enrolled, and completed work that has not yet been invoiced.
- Patterns over time. Sites and vendors that consistently overbill, lagging invoices, and the share of spend going to startup versus patient activity; trends a single month’s report cannot show.
Every finding links back to the underlying raw data and can be viewed by site, visit, procedure, and site admin fee. Because payment history is now connected to trial performance, those patterns also feed Condor’s forecasting, giving clinical operations and finance teams projected spend grounded in how vendors actually bill rather than in invoices alone.
The launch extends the AI capabilities Condor introduced with its Clinical Finance Agent in September, and expands the platform’s investigator grants functionality as a foundation for more autonomous, agentic workflows.
“The next step is moving from analysis on demand to continuous monitoring,” said Fox. “Condor’s AI will watch payment and performance data as it arrives and flag anomalies the moment they appear. And the site-level evidence it builds gives sponsors a stronger position when they negotiate CRO change orders.”
AI-powered investigator grants intelligence is available now. To see it in action, book a demo at https://condorsoftware.com/book-a-demo.
About Condor
Condor Software is the AI platform for biopharma R&D teams. It automatically centralizes clinical, operational, and financial data; automates various workflows — like budgeting, forecasts, month-end closes, accruals, and change order management; and then surfaces patterns, flags risks, bridges context across functions, and delivers the “why” behind the numbers. Founded by Jen Kyle, Condor is backed by Insight Partners, Felicis, 645 Ventures, Pamir Ventures, and SNR Ventures, and is trusted by leading biopharma companies worldwide — including Acadia Pharmaceuticals, BridgeBio Pharma, Madrigal Pharmaceuticals, and Stemline Therapeutics. Learn more at condorsoftware.com.
Media Contact:
Joseph Roualdes
joe.roualdes@condorsoftware.com
415.823.2136
View original content to download multimedia:https://www.prnewswire.com/news-releases/condor-unveils-ai-powered-investigator-grants-intelligence-302913187.html
SOURCE Condor Software
